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Purpose: The purpose of this study was to assess predictability, efficacy, safety and stability 
in patients who received a toric implantable collamer lens to correct moderate to high myopic 
astigmatism.
Methods: Forty-three eyes of 23 patients underwent implantation of a toric implantable 
collamer lens (STAAR Surgical Inc) for astigmatism correction. Mean spherical refraction 
was −4.98 ± 3.49 diopters (D) (range: 0 to −13 D), and mean cylinder was −2.62 ± 0.97 D 
(range: −1.00 to −5.00 D). Main outcomes measures evaluated during a 12-month follow-up 
included uncorrected visual acuity (UCVA), refraction, best-corrected visual acuity (BCVA), 
vault, and adverse events.
Results: At 12 months the mean Snellen decimal UCVA was 0.87 ± 0.27 and mean BCVA was 
0.94 ± 0.21, with an efficacy index of 1.05. More than 60% of the eyes gained $1 line of BCVA 
(17 eyes, safety index of 1.14). The treatment was highly predictable for spherical equivalent 
(r2 = 0.99) and astigmatic components: J0 (r2 = 0.99) and J45 (r2 = 0.90). The mean spherical 
equivalent dropped from −7.29 ± 3.4 D to −0.17 ± 0.40 D at 12 months. Of the attempted spheri-
cal equivalent, 76.7% of the eyes were within ±0.50 D and 97.7% eyes were within ±1.00 D, 
respectively. For J0 and J45, 97.7% and 83.7% were within ±0.50 D, respectively.
Conclusion: The results of the present study support the safety, efficacy, and predictability of 
toric implantable collamer lens implantation to treat moderate to high myopic astigmatism.
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Introduction
Clinical results of posterior phakic intraocular lenses (pIOLs) have confirmed this 
procedure as a promising treatment option for patients who cannot undergo kera-
torefractive procedures.1 The main advantages are the correction of higher levels 
of myopia, hyperopia, and astigmatism and the reversibility of the procedure.2–12 
Presently, one of the most successful pIOL, known as implantable collamer lens 
(ICL), is the Visian ICLV4 manufactured by STAAR Surgical (Monrovia, CA; 
Figure 1). The Visian ICL is the only posterior pIOL currently under revision for 
approval by the United States Food and Drug Administration (FDA) for the treat-
ment of astigmatism.10
Several studies have been published on an anterior chamber iris-fixated toric 
pIOL13–17 demonstrating a significant reduction in spherical and astigmatic refractive 
errors. However concerns still exist regarding potentially induced progressive endothe-
lial cell loss.18 The recently published outcomes of the toric ICL8–12 showed good efficacy 
and predictability. Additionally, in cases in which keratorefractive or other alternative Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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refractive procedures were not a good or feasible option, toric 
ICL implantation showed promising results.19–22
The purpose of this study was to assess safety, efficacy, 
predictability, and stability in patients who undergo toric ICL 
implantation to correct moderate to high myopic astigmatism 
with follow-up visits up to 12 months.
Patients
We prospectively studied 43 eyes of 23 patients, 17 (73.9%) 
females and 6 (26.1%) males, who underwent implantation 
of a toric ICL to correct myopic astigmatism at the Medipolis 
Eye Centre (Antwerp, Belgium). Mean patient age was 
34.41 ± 9.42 years (range: 22 to 49 years). Table 1 shows 
the demographic data prior to surgery and parameters of 
implanted lenses.
The inclusion criteria were best-corrected distance visual 
acuity (BCVA) of 20/40 or better, stable refraction and clear 
central cornea. The exclusion criteria included age ,22 years, 
anterior chamber depth ,2.8 mm from endothelium, 
endothelial cell density ,2000 cell/mm2, cataract, history of 
glaucoma or retinal detachment, macular degeneration or 
retinopathy, neuro-ophthalmic diseases, and history of ocular 
inflammation. Before the TICL implantation, patients had a 
complete ophthalmologic examination, including refraction, 
keratometry, corneal topography, endothelial cell count, 
pachymetry, slit-lamp microscopy, Goldmann applanation 
tonometry, and binocular indirect ophthalmoscopy. The 
targeted refraction was emmetropia in all cases.
Toric ICL is a pIOL manufactured with an haptic design 
identical to the spherical ICL2 in terms of size, thickness, and 
shape, with central convex/concave optical zone, and cylinder 
as necessary to address each patient’s astigmatic condition.8 
Toric ICL power calculation was performed using the software 
provided by the manufacturer. Toric ICL is manufactured to 
minimize rotation and required the surgeon to rotate the toric 
ICL no more than 22.5° from the horizontal meridian. Each 
toric ICL comes with a guide demonstrating the amount and 
direction of rotation from the horizontal axis required of the 
toric ICL to exactly align the toric ICL cylinder axis to the 
patients’ required cylinder correction. All surgeries in this 
study were performed by one experienced surgeon (ELM) 
using topical and intracameral anesthesia. On the day of sur-
gery, 0.5% tropicamide and 5% phenylephrine HCl were 
serially instilled for pupil dilation. Fifteen minutes before 
surgery a drop of preservative-free oxybuprocaine HCl 0.4% 
was instilled, followed by two to four drops of povidone 
iodine 5%. The left eye underwent surgery first. Povidone 
iodine 10% (Isobetadine; Viatris, Bad Homburg, Germany) 
was applied to the eyelids, the patient was draped and a lid 
speculum inserted. Four drops of preservative-free oxybupro-
caine HCl 0.4% were used to further anaesthetize each eye. 
Three minutes before the start of surgery povidone iodine 5% 
was administered to the ocular surface. The lens was removed 
from the sealed glass container and loaded inside the cartridge 
under the surgical microscope. The inner side of the cartridge 
was lubricated with methylcellulose and balanced salt solution. 
The lens was loaded making sure that both longitudinal edges 
of the haptic were symmetrically tucked under the edge of the 
cartridge with the lens vaulted anteriorly. The coaxial forceps 
designed by Zaldivar for ICL loading (Asico, Westmont, IL) 
was used to pull the lens through the cartridge tunnel. 
  Inspection of the lens inside the tunnel was done to exclude 
twisting of the lens which helped making the injection inside 
the anterior chamber symmetrical, smooth, and reproducible. 
A preinked surgical marker was used to mark the target axis 
Figure 1 Toric visian iCLv4 lens. Red dotted line indicates the eye’s horizontal 
axis. Yellow line indicates lens horizontal axis connecting the two diamond-shaped 
marks of the toric iCL. The arrows indicate that the surgeon aligned the lens at 
5° counterclockwise from the horizontal meridian.
Table 1 Descriptive statistics for demographic data of patients 
and characteristics of implanted toric implantable collamer lens
Mean SD Range  
[min, max]
Age (years) 34.41 9.42 [22, 49]
Refractive sphere (D) −5.98 3.49 [−13.5, 0]
Refractive cylinder (D) −2.62 0.97 [−5, −1]
Flat keratometry 43.10 1.72 [39.63, 47.13]
Steep keratometry 45.38 1.84 [40.75, 49.00]
iCL size (mm) 12.09 0.42 [11.5, 12.5]
iCL sphere (D) −13.13 4.09 [−21, −4.50]
iCL cylinder (D) 3.24 1.32 [0.5, 6.0]
white-white (mm) 11.66 0.35 [10.8, 12.5]
ACD (mm) 3.19 0.32 [2.80, 3.82]
Corneal thickness (μm) 514.5 50.2 [420, 625]
Abbreviations:  iCL,  implantable  collamer  lens;  ACD,  anterior  chamber  depth 
from endothelium; SD, standard deviation. Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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for toric ICL implantation using the previous dots marked at 
the slit lamp as reference for 0°–180°. This provided the sur-
geon with extended lines over the cornea and pupil to facilitate 
alignment. A 1.0-mm side-port was made at 10 o’clock in the 
left eye and at 5 o’clock in the right eye followed by injection 
of intracameral preservative-free lidocaine 1% followed by 
viscoelastic (methylcellulose) with caution to not over-fill the 
anterior chamber. A 3-step temporal clear corneal incision: 
first a 600-μm groove is made; tilting the tip of the knife a 
little bit upward and then parallel to the iris plane and enter 
the anterior chamber. The size of the incision was 2.6 mm; 
this size allows smooth injection and has been reported to have 
negligible effect on postoperative astigmatism.
Firmly grasping the eye with the forceps, the tip of the 
cartridge was placed at the edge of the incision and the lens 
was slowly injected. The surgeon paid attention to the distal 
footplate to unfold in the anterior chamber before the trailing 
footplate was injected out of the cartridge. This prevents the 
lens from unfolding upside down in the anterior chamber. 
Once the lens unfolded in the anterior chamber the marks on 
the distal and proximal footplates were checked for proper 
orientation. Using the side-port and with Vukich’s or Batlle’s 
manipulator, the distal haptics were tucked under the iris. All 
manipulations were as peripheral as possible with no instru-
ments touching the optic or crossing the pupillary zone. The 
proximal footplates were then tucked under the iris through 
the main incision. Using the line marks on the cornea we 
checked for toric ICL alignment. If rotation was needed we 
gently used the manipulator over the peripheral haptic and 
aligned the lens. Verification of lens centration and alignment 
is then done. Flush of viscoelastic was done by injection of 
saline through the side-port and pushing down on the main 
incision. At the completion of the procedure we injected 
intracameral preservative-free antibiotics (vancomycin 
1 mg/mL), checked sealing of the incision and administered 
one drop of dorzolamide 20% and timolol 5%. In the recovery 
room a tablet of acetazolamide 250 mg was administered orally 
to reduce further the intraocular pressure. Two hours after 
surgery the vault and alignment of the toric ICL was checked 
at the slit-lamp and the intraocular pressure was measured.
The tenets of the Declaration of Helsinki were followed 
in this study. Informed consent stating the potential risks and 
benefits of the lens implantation was obtained from all 
patients prior to surgery.
Follow-up visits were done at week 1, and months 1, 3, 6, 
and 12 postoperatively. All eyes were examined at each post-
operative visit. Uncorrected visual acuity (UCVA), BCVA, 
slit-lamp examination, refraction, central separation between 
the ICL and the crystalline lens (vault) with slit lamp 
examination, and tonometry were evaluated. Vault value was 
assessed by comparing the separation between the lens and the 
posterior surface of the TICL to the corneal thickness using an 
optical section during routine slit-lamp examination. Estimation 
was registered in 0.25 steps (ie, 0.25 corneal thickness [CT], 
0.5 CT, 0.75 CT, 1 CT, 1.25 CT, etc). For averaging, visual 
acuities were converted to logMAR and then the means and 
standard deviations were back calculated to Snellen acuity. 
Assessment of toric ICL outcomes was based on a comparison 
of preoperative with postoperative values of BCVA and UCVA 
for efficacy and safety and the achieved versus expected refrac-
tive outcomes postoperatively for predictability. Efficacy index 
(ratio of postoperative UCVA over preoperative BCVA) and 
safety index (ratio of postoperative over preoperative BCVA) 
were also calculated. Spherocylindrical refractive results were 
converted into vector expressed by 3-dioptric powers: M, J0, 
and J45; with M being equal to the spherical equivalent of the 
given refractive error, and J0 and J45 the two Jackson cross 
cylinders equivalent to the conventional cylinder. Manifest 
refractions in conventional script notation (S [sphere], 
C [  cylinder], α [axis]) were converted to power vector coordi-
nates by the following formulas: 
M = S + C/2; J0 = (−C/2)*cos (2α) and  
   J 45 = (−C/2)*sin (2α)23.
Data analysis was performed using SPSS for Windows 
(version 16.01; SPSS Inc, Chicago, IL). Normality of data 
distribution was checked by Kolmogorov–Smirnov test. 
  Comparison of means with nonparametric Wilcoxon signed 
rank test. Hotelling T 2   test of multivariate analysis was used 
to explore statistically significant differences for refractive 
values and visual acuity outcomes. Differences were considered 
to be statistically significant when the P value was ,0.05.
Results
No complications occurred during the surgical procedures. No 
eye needed explantation and only one eye needed repositioning 
due to off-axis alignment 10 months after   implantation. 
  Decentration of the toric ICL optic was not observed, and no 
case of pupillary block was detected. At 12 months postsur-
gery, the mean spherical error was −0.06 ± 0.34 D (ranging 
from 1.00 to −1.00 D) and the mean cylinder value 
was −0.20 ± 0.43 D (ranging from 0 to −1.50 D).
In relation to predictability, Figure 2 shows the distribution 
of manifest refractive cylinder before toric ICL implantation 
compared with the 12-month visit outcomes. At the 12-month 
follow-up visit, 43 (100%) of eyes with the toric ICL Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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had #2.0 D of cylinder, compared with 17 (39.5%) preopera-
tively, with 39 (90.7%) eyes having a refractive   cylinder #1.0 D. 
Furthermore, no eyes (0.0%) preoperatively had refractive 
cylinder of 0.50 D, whereas 36 eyes (83.7%) had #0.5 D and 
35 (81.4%) had #0.25 D of refractive cylinder at 12 months. 
The deviation of the achieved from the expected M refraction 
was calculated (see Figure 3). At 12 months, the mean M 
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Figure 2 Preoperative (preop) versus 12-month postoperative refractive cylinder in 
diopters (d) after toric implantable collamer lens implantation.
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Figure 3 Plots of achieved against attempted correction (predictability) of spherical 
equivalent (M) in diopters (D) and the astigmatic components ( J0 and J45) 12 months 
after toric implantable collamer lens implantation. Coefficients of determination (r2) 
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Figure 4 Time course of the spherical equivalent (M) in diopters (stability) after 
toric implantable collamer lens implantation.
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Figure 5 Scatter plot of the astigmatic vectors (J0 and J45) before and 12 months 
after toric implantable collamer lens implantation. The more central location of 
postoperative data around 0 represents the reduction of preoperative astigmatism 
by the implantation of the toric implantable collamer lens. Note that (0,0) represents 
an eye free of astigmatism.
was −0.17 ± 0.40 D with 33 (76.7%) of the eyes within ±0.50 
D and 42 (97.7%) were within ±1.00 D of the desired M 
refraction (r2 = 0.99). For the astigmatic components, 42 eyes 
(97.7%) and 36 (83.7%) of eyes were within ±0.50 D for J0 
(r2 = 0.99) and J45 (r2 = 0.90), respectively.
The improvement in M refractive error is graphically 
illustrated in Figure 4. The mean M dropped significantly 
from −7.29 ± 3.4 D to −0.17 ± 0.40 D at 12 months (P , 0.05). 
Figure 5 shows the astigmatic components of the power vector 
as represented by the two-dimensional vector plot (J0, J45) 
where the tight distribution of points around zero is evident 
12 months after surgery compared to preoperative data. The 
origin in this graph (0,0) represents an eye free of astigmatism. 
A multivariate Hotelling T 2   test confirmed that the mean 
power vector after surgery was not significantly different from 
a vector of zero length (P = 0.3256).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Figure 6 shows the safety results for toric ICL implantation. 
Twelve months after surgery none of the examined eyes had 
lost .2 lines of BCVA; one eye lost 2 lines, two (4.7%) eyes 
lost 1 line, 10 eyes (23.3%) did not change after surgery, while 
13 eyes (30.2%) gained 1 line, 14 (32.6%) eyes gained 2 lines, 
and three eyes gained .2 lines of BCVA. The safety index at 
12 months was 1.14. Figure 7 represents the cumulative BCVA 
at baseline and 12 months after surgery. All eyes showed a 
BCVA of 20/63 or better with more than 93.0% (40 eyes) of 
eyes with BCVA of 20/32 or better and also an increase in the 
amount of eyes with BCVA of 20/20 or better, from 30.2% 
(13 eyes) at baseline to 69.8% (30 eyes) after 12 months.
In relation to the efficacy, Figure 8 shows the changes in 
UCVA and BCVA. Before surgery the mean Snellen decimal 
UCVA was 0.09 ± 0.07 (range: 0.05 to 0.2) while BCVA 
was 0.83 ± 0.18 (range: 0.5 to 1.2). At 12 months, the mean 
UCVA was 0.87 ± 0.27 (range 0.2 to 1.2) and the mean 
BCVA was 0.94 ± 0.21 (range 0.5 to 1.2). The overall effi-
cacy was 1.05. At the 12-month examination 25 (58.1%) 
eyes had 20/20 or better UCVA, compared with 13 (30.2%) 
BCVA at baseline. Furthermore, 31 (72%) eyes had 12-month 
postoperative UCVA equal to or better than preoperative 
BCVA and 12 (28%) eyes having 12-month postoperative 
UCVA lower than preoperative BCVA.
During the entire follow-up period we did not observe any 
chronic increased postoperative intraocular pressure (IOP). 
No pupillary block was detected. Anterior subcapsular cataract 
development was not observed over the entire follow-up 
period and mean IOP was 14.4 ± 3.3 mmHg (ranging from 8 
to 20 mmHg). Mean vault was 0.94 ± 0.20 CT and changes 
during the follow-up period were very small without statistical 
significance during the follow-up period (P . 0.05).
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Discussion
The present prospective study of 43 eyes of 23 patients 
analyzed the correction of myopic astigmatism with toric 
ICL implantation. The aim of the study was to determine in 
our series whether this technique is a safe, predictable, and 
effective alternative for correcting myopia and astigmatism 
using pIOLs.
Our outcomes revealed that toric ICL implantation is 
highly predictable, stable and safe up to a period of 12 months 
postsurgery. The majority of eyes maintained or improved 
their BCVA, which resulted in a high safety index (1.14). 
Only one eye lost 2 lines of BCVA at 12 months. Conversely 
more than 60% of eyes showed a gain in BCVA (Figure 6). 
In addition, over 80% of eyes had BCVA of 20/25 or better 
at 12 months and the percent of eyes with BCVA of 20/20 
or better increased from 30% preoperatively to 70% after 
toric ICL implantation (see Figure 7 for a full description of 
cumulative visual acuity pre- and postsurgery).
In order to compare with previous studies reporting data 
of the toric ICL, the US FDA toric ICL clinical study8 showed 
that the toric ICL implantation is a predictable and effective 
method for treating moderate to high astigmatism. In that 
study 76.4% of patients gained $1 line of BCVA postopera-
tively and 76.5% of cases had postoperative UCVA better 
than or equal to preoperative BCVA, with 1.6% of eyes 
lost $2 lines of BCVA after 12 months. It was also reported 
an improvement in mean manifest M value from −9.36 D 
preoperatively to 0.05 D postoperatively, with 76.9% of eyes 
within ±0.50 D and 97.3% within ±1.00 D as well a reduction 
of 73.6% in astigmatism with a mean manifest refractive 
cylinder reduction from 1.93 D to 0.51 D at 12 months. 
Chang and Lau9 analyzed the toric ICL on 44 Asian eyes at 
6 months showing comparable outcomes to the FDA toric 
ICL study.8 Recently, Alfonso et al10 analyzed 55 eyes 
implanted with the toric ICL at 12 months and reported high 
correlations between attempted and achieved refractive 
changes for sphere and cylinder components (r2 $ 0.97) 
with 100% of eyes within ±1.00 D, and more than 90% of 
eyes within ±0.50 D. A similar study of these authors11 
reported the analysis of the toric ICL in highly astigmatic 
eyes (.4 D of cylinder) showing also good outcomes with 
93.3% of eyes having less than 1.00 D of cylinder. The mean 
spherical equivalent was −0.31 ± 0.42 D (range −1.00 to 
0.75 D), with more than 70% of eyes within ±0.50 D of the 
target. For the astigmatic components, 93.3% of eyes were 
within ±1.00 D of J0 and all eyes were within ±1.00 D of J45. 
The results of our study agree with those previously 
reported by these authors.
In addition, it is interesting to consider that toric ICL 
implantation has also been used in cases where keratorefrac-
tive or alternative corrective refractive procedures were not 
a feasible option. For example, Kamiya et al19 reported a 
marked improvement in UCVA and BCVA in two patients 
with nonprogressive keratoconus, showing a reduction in the 
manifest refraction from −10.00 −6.00 × 100° D and −8.00 
−2.75 × 100° D to +0.50 −1.00 × 90° D and −0.25 
−1.25 × 100° D after surgery. Mertens et al20 reported a 
bilateral implantation of a custom-designed toric ICL in a 
patient with preoperative subjective refractive cylinder of 
−5.25 × 6° in the right eye and −5 × 176° in the left eye, 
changing to −0.5 × 77° and −0.5 × 115° after toric ICL 
implantation, respectively. UCVA improved to 20/20 in the 
right eye and 20/16 in the left eye, and BCVA improved to 
20/16 in the right eye and 20/10 in the left eye. In a series of 
15 eyes with spherical ICL and toric ICL implantation after 
penetrating keratoplasty, Alfonso et al21 reported an improve-
ment in BCVA, with 80% of eyes having BCVA of 20/40 
or better at 24 months postoperatively. About 46% of eyes 
gained $1 lines of BCVA, 52% of all eyes did not change 
their BCVA, and no patients lost $1 lines of BCVA at 
  follow-up. Furthermore, 66.6% of eyes were within ±0.50 D 
in M and astigmatic components showing values nearly 
100% within ±1.00 D in all eyes. Good outcomes of these 
previous studies should be taken into account to consider 
toric ICL implantation.
In relation to adverse effects, the main concern related to 
ICL implantation are anterior subcapsular cataract and 
increased IOP,24–28 presumably as a result of mechanical contact 
of the ICL with the anterior lens capsule, or pigment dispersion 
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and pupillary block due to angle closure, respectively. In our 
study, no chronic increased postoperative IOP was found 
and no eye developed anterior subcapsular cataract over the 
entire follow-up period. Furthermore, mean central separa-
tion between the toric ICL and the crystalline lens (vault) 
during entire follow-up of this study was good and stable. 
Longer follow-up is needed to properly analyze long-term 
effects of the Toric ICL on the ocular structures.
To summarize, the results of the present study analyzing 
the toric ICL for myopic astigmatism correction showed that 
this procedure is safe, stable, and predictable during the 
12 months period of follow-up. Our results agree with those 
reported with this lens previously.
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